Chronic obstructive pulmonary disease (COPD) is a common lung condition most often caused by smoking. It has been suggested that having COPD itself or using certain treatments to manage COPD may increase the risk of developing type 2 diabetes mellitus (DM). Additionally, people with COPD are at risk of having chest infections (known as exacerbations). It is not clear whether having DM, which is associated with increased risk of some infections (such as cellulitis or pneumonia), is also associated with increased exacerbation risk in COPD patients. Frequent exacerbators of COPD are commonly on high dose inhaled corticosteroids and have repeated courses of prednisolone for treatment of their exacerbations, and it is not known whether DM is more common in frequent exacerbators of COPD due to steroid use. This study will investigate these factors. This information will be of benefit to both patients and health care providers by potentially identifying modifiable risk factors which may in turn alter treatment.
Clinical trials investigating drugs used as maintenance therapy for Chronic obstructive pulmonary disease (COPD) do not usually target onset diabetes as a primary outcome and therefore there is a need to directly re-examine whether this association holds in a contemporary cohort of COPD patients. The Objective of this study is to investigate the risk factors associated with developing Type II Diabetes (DM) among patients with COPD. A cohort of COPD patients with incident DM will be 1:5 matched to patients without DM. Risk factors will be measured as logistic regression will be used to determine which risk factors are associated with incidence of DM. Patients classified as frequent exacerbators will be identified and the associations will be investigated.
COPD Exacerbation Status
- Association between incident diabetes and exacerbation status
Alicia Gayle - Chief Investigator - Imperial College London
Alicia Gayle - Corresponding Applicant - Imperial College London
Chris D Poole - Collaborator - Digital Health Labs Limited
Clare Bolton - Collaborator - Boehringer-Ingelheim - UK
Jennifer Quint - Collaborator - Imperial College London
Scott Dickinson - Collaborator - Boehringer-Ingelheim - UK
Practice Level Index of Multiple Deprivation